comparemela.com
Home
Live Updates
Discussing New Phase 2 Findings on Lutikizumab for Hidradeni
Discussing New Phase 2 Findings on Lutikizumab for Hidradeni
Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH
Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
Related Keywords
Massachusetts ,
United States ,
American ,
Alexa Kimball ,
Harvard Medical School ,
American Academy Of Dermatology ,
Annual Meeting ,
Hidradenitis Suppurativa Clinical Response ,
Massachusetts General Hospital ,
Numeric Rating Scale ,
Global Assessment ,
Dhs ,
Hidradenitis Suppurativa ,
Lutikizumab ,
Anti Tnf ,
Interleukin ,
Phase 2 ,
Aad ,
Late Breaking ,